Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826)
16.35
+0.63 (4.01%)
Sep 30, 2026, 4:08 PM HKT
HKG:6826 Revenue
Shanghai Haohai Biological Technology had revenue of 607.69M CNY in the quarter ending June 30, 2026, a decrease of -11.40%. This brings the company's revenue in the last twelve months to 2.32B, down -10.28% year-over-year. In the year 2025, Shanghai Haohai Biological Technology had annual revenue of 2.45B, down -8.71%.
Revenue (ttm)
2.32B CNY
Revenue Growth
-10.28%
P/S Ratio
2.70
Revenue / Employee
1.16M CNY
Employees
1,999
Market Cap
7.23B HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.45B | -233.36M | -8.71% |
| Dec 31, 2024 | 2.68B | 44.76M | 1.70% |
| Dec 31, 2023 | 2.63B | 531.47M | 25.27% |
| Dec 31, 2022 | 2.10B | 353.32M | 20.19% |
| Dec 31, 2021 | 1.75B | 425.69M | 32.14% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Lepu Biopharma | 1.14B |
| Alphamab Oncology | 598.06M |
| Suzhou Ribo Life Science | 536.18M |
| CStone Pharmaceuticals | 490.92M |
| Nanjing Leads Biolabs | 246.16M |
| CARsgen Therapeutics Holdings | 157.72M |
| Abbisko Cayman | 112.29M |
| Ascletis Pharma | 1.09M |